Control of regulatory T cell homeostasis and function by Notch signaling
通过 Notch 信号传导控制调节性 T 细胞稳态和功能
基本信息
- 批准号:9913447
- 负责人:
- 金额:$ 44.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-05-04 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:AllergicAllergic inflammationAsthmaAutoantibodiesAutoimmune DiseasesAutoimmune ProcessAutoimmunityCell CompartmentationCell Differentiation processCell LineageCell ProliferationCell physiologyCellsChronicDiseaseEnsureFOXP3 geneFunctional disorderGenetic TranscriptionGoalsHelper-Inducer T-LymphocyteHomeostasisHumanImmuneImmune ToleranceImmune responseImmunityImpairmentIn VitroIndividualInflammationInflammatoryLeadLigandsMediatingMusMutationNOTCH3 geneNatureOutcomePathogenesisPathogenicityPathway interactionsPeripheralPhysiologicalPlayProteinsReceptor SignalingRegulationRegulatory T-LymphocyteRheumatoid ArthritisRoleSignal PathwaySignal TransductionSpecificitySystemic Lupus ErythematosusT-LymphocyteTh1 CellsTh2 CellsTherapeuticTranscriptional ActivationTranscriptional Regulationallergic airway inflammationcytokinefunctional outcomesgraft vs host diseasein vivoloss of functionloss of function mutationnotch proteinnovelnovel therapeuticsprogramsprotein functionreceptorresponserestorationtranscriptome
项目摘要
Abstract
Foxp3+ regulatory T (TR) play a requisite role in peripheral immunological tolerance and in restraining
exuberant immune responses. Elucidating mechanisms that control TR cell responses is of pivotal importance
to the restoration of tolerance in diseases of chronic inflammation and autoimmunity. Relevant to this goal is
our recent determination of a critical role for the Notch pathway in regulating the peripheral TR cell
compartment. TR cell-specific deletion of Notch1 antagonized T helper (Th)1 responses and protected against
graft versus host disease, while TR cell-specific constitutive expression of the intracellular domain of Notch1
led to lymphoproliferation, Th1 cell dysregulation and autoimmunity. We have also demonstrated that TR cell-
specific loss of function Notch pathway mutations that incapacitate signaling via all Notch receptors (Pofut1
deletion) or canonical pathway signaling (Rbpj deletion) but not deletion of Notch1 or Notch2, protected against
allergic airway inflammation, indicating that individual Notch receptors on TR cells mediated regulation of
distinct Th cell programs. Some of the effects of Notch signaling in TR cells involved transcriptional activation
via the canonical Notch pathway co-factor RBPJ. Yet others appeared to involve activation of the non-
canonical mechanisms. Accordingly, We hypothesize that Notch signaling fulfills an important physiological
role in negatively regulating TR cells to ensure optimal immune homeostasis. Excessive activation of this
pathway would result in TR cell dysfunction, leading to immune dysregulation, inflammation and autoimmunity.
We further hypothesize that individual Notch receptors on TR cells fulfill non-redundant roles in controlling Th
cell responses, with Notch1 regulating Th1 and Notch4 Th2 cell responses, respectively. We also hypothesize
that the capacity of individual Notch receptors on TR cells to mediate distinct immune regulatory outcomes is
reflected by hierarchal Notch receptor-ligand interactions and by distinct transcriptional circuitries activated by
the respective Notch receptors. We propose under Aim 1 to elucidate mechanisms by which sustained Notch1
signaling in TR cells promotes dysregulated Th1 cell responses by enabling complete Th1 cell reprogramming
of TR cells, and the role of T follicular regulatory (TFR) cell subversion by Notch1 signaling in inciting intense
humoral autoimmunity. Under Aim 2, we will examine mechanisms by which Notch signaling in TR cells, most
notably that by Notch4 (and possibly Notch3), regulates Th2 cell responses in allergic airway inflammation,
while Aim 3 will explore mechanisms by which signaling via different Notch receptors in TR cells leads to
distinct functional outcomes, including ligand specificity of the respective receptor expressed on TR cells and
the nature of the downstream transcriptional programs activated upon Notch1 versus Notch4 signaling. The
proposed studies will identify novel mechanisms by which Notch signaling controls TR cell activities relevant to
different inflammatory paradigms, and will have bearing on common immune dysregulatory diseases, including
autoimmune disorders, graft versus host disease and allergic inflammation such as in asthma.
摘要
Foxp 3+调节性T(TR)在外周免疫耐受中起着必要的作用,
旺盛的免疫反应阐明控制TR细胞反应的机制至关重要
恢复慢性炎症和自身免疫性疾病的耐受性。与这一目标相关的是
我们最近确定了Notch通路在调节外周TR细胞中的关键作用,
车厢TR细胞特异性Notch 1缺失拮抗辅助性T细胞(Th)1应答,并保护
移植物抗宿主病,而TR细胞特异性组成型表达Notch 1的细胞内结构域
导致淋巴细胞增生、Th 1细胞失调和自身免疫。我们还证明了TR细胞-
特异性功能丧失Notch途径突变,其使通过所有Notch受体(Pofut 1)的信号传导丧失能力
缺失)或经典途径信号传导(Rbpj缺失),但不缺失Notch 1或Notch 2,
过敏性气道炎症,表明TR细胞上的单个Notch受体介导了
不同的Th细胞程序。Notch信号在TR细胞中的一些作用涉及转录激活
通过经典Notch途径辅因子RBPJ。然而,其他人似乎涉及激活非-
规范机制因此,我们假设Notch信号传导实现了一个重要的生理学功能。
在负调节TR细胞以确保最佳免疫稳态中的作用。过度激活这个
在某些情况下,TR通路可能导致TR细胞功能障碍,导致免疫失调、炎症和自身免疫。
我们进一步假设TR细胞上的单个Notch受体在控制Th
细胞应答,Notch 1分别调节Th 1和Notch 4 Th 2细胞应答。我们还假设
TR细胞上单个Notch受体介导不同免疫调节结果的能力,
反映在分级Notch受体-配体相互作用和不同的转录电路激活,
各自的Notch受体在目标1下,我们提出阐明维持Notch 1的机制,
TR细胞中的信号传导通过使完整的Th 1细胞重编程而促进失调的Th 1细胞应答
以及Notch 1信号转导对T滤泡调节细胞(TFR)的颠覆作用,
体液性自身免疫在目标2下,我们将研究TR细胞中Notch信号传导的机制,
值得注意的是,通过Notch 4(可能还有Notch 3),调节过敏性气道炎症中的Th 2细胞应答,
而Aim 3将探索通过TR细胞中不同Notch受体的信号传导导致
不同的功能结果,包括TR细胞上表达的相应受体的配体特异性,
Notch 1与Notch 4信号传导激活的下游转录程序的性质。的
提出的研究将确定Notch信号转导控制TR细胞活动的新机制,
不同的炎症范例,并将与常见的免疫失调疾病,包括
自身免疫性疾病、移植物抗宿主病和过敏性炎症如哮喘。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Talal Amine Chatila其他文献
Talal Amine Chatila的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Talal Amine Chatila', 18)}}的其他基金
Targeting microbial dysbiosis in Food Allergy to restore tolerance
针对食物过敏中的微生物失调以恢复耐受性
- 批准号:
10549764 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Targeting microbial dysbiosis in Food Allergy to restore tolerance
针对食物过敏中的微生物失调以恢复耐受性
- 批准号:
10185766 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10210940 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10592358 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Targeting microbial dysbiosis in Food Allergy to restore tolerance
针对食物过敏中的微生物失调以恢复耐受性
- 批准号:
10359843 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10392449 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Genetic and Epigenetic Programming of Allergic Airway Inflammation
过敏性气道炎症的遗传和表观遗传编程
- 批准号:
10169796 - 财政年份:2020
- 资助金额:
$ 44.25万 - 项目类别:
Effect of IL-4RαR576 variant on response to Dupilumab in children with Asthma
IL-4RαR576 变异对哮喘儿童 Dupilumab 反应的影响
- 批准号:
10592379 - 财政年份:2019
- 资助金额:
$ 44.25万 - 项目类别:
Effect of IL-4RαR576 variant on response to Dupilumab in children with Asthma
IL-4RαR576 变异对哮喘儿童 Dupilumab 反应的影响
- 批准号:
10386768 - 财政年份:2019
- 资助金额:
$ 44.25万 - 项目类别:
Effect of IL-4RαR576 variant on response to Dupilumab in children with Asthma
IL-4RαR576 变异对哮喘儿童 Dupilumab 反应的影响
- 批准号:
9912720 - 财政年份:2019
- 资助金额:
$ 44.25万 - 项目类别:
相似海外基金
Human secreted IgD: structure, interactions and mechanisms in allergic inflammation and asthma
人类分泌的 IgD:过敏性炎症和哮喘的结构、相互作用和机制
- 批准号:
MR/V010557/1 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Research Grant
Environmental Pollutants Potentiate Allergic Inflammation via Functional Axis of Aryl hydrocarbon Receptor, ROS, and CaMKII in Asthma
环境污染物通过芳基烃受体、ROS 和 CaMKII 功能轴在哮喘中加剧过敏性炎症
- 批准号:
10404097 - 财政年份:2019
- 资助金额:
$ 44.25万 - 项目类别:
Environmental Pollutants Potentiate Allergic Inflammation via Functional Axis of Aryl hydrocarbon Receptor, ROS, and CaMKII in Asthma
环境污染物通过芳基烃受体、ROS 和 CaMKII 功能轴在哮喘中加剧过敏性炎症
- 批准号:
9817088 - 财政年份:2019
- 资助金额:
$ 44.25万 - 项目类别:
Environmental Pollutants Potentiate Allergic Inflammation via Functional Axis of Aryl hydrocarbon Receptor, ROS, and CaMKII in Asthma
环境污染物通过芳基烃受体、ROS 和 CaMKII 功能轴在哮喘中加剧过敏性炎症
- 批准号:
10161717 - 财政年份:2019
- 资助金额:
$ 44.25万 - 项目类别:
Targeting microRNA (miRNA) as a unified therapeutic approach to the treatment of asthma and allergic inflammation
靶向 microRNA (miRNA) 作为治疗哮喘和过敏性炎症的统一治疗方法
- 批准号:
nhmrc : 1004267 - 财政年份:2011
- 资助金额:
$ 44.25万 - 项目类别:
NHMRC Project Grants
SP-A Regulation of Host Response in Asthma and Allergic Inflammation
SP-A 调节哮喘和过敏性炎症中的宿主反应
- 批准号:
8325217 - 财政年份:2009
- 资助金额:
$ 44.25万 - 项目类别:
Dehydroxymethylepoxyquinomicin(DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodeling in murine models of asthma
脱羟甲基环氧喹诺星 (DHMEQ) 是一种新型 NF-kappaB 抑制剂,可抑制哮喘小鼠模型中的过敏性炎症和气道重塑
- 批准号:
21659206 - 财政年份:2009
- 资助金额:
$ 44.25万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Role of IL-3 in allergic inflammation: modulation of basophils, mast cells, eosinophils and remodelling in asthma.
IL-3 在过敏性炎症中的作用:调节嗜碱性粒细胞、肥大细胞、嗜酸性粒细胞和哮喘重塑。
- 批准号:
nhmrc : 471481 - 财政年份:2008
- 资助金额:
$ 44.25万 - 项目类别:
NHMRC Project Grants
IMMUNOGENETIC DISEASES-ALLERGIC INFLAMMATION TO AIRWAY REMODELING IN ASTHMA
免疫性疾病——哮喘中气道重塑的过敏性炎症
- 批准号:
7725315 - 财政年份:2008
- 资助金额:
$ 44.25万 - 项目类别:
IMMUNOGENETIC DISEASE-ALLERGIC INFLAMMATION TO AIRWAY REMODELING IN ASTHMA
哮喘气道重塑的免疫性疾病过敏性炎症
- 批准号:
7609596 - 财政年份:2007
- 资助金额:
$ 44.25万 - 项目类别: